SOLIGENIX, INC. (SNGX) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, SOLIGENIX, INC.'s filing signal continuing negative.

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing treatments for rare diseases, operating through two segments: Specialized BioTherapeutics and Public Health Solutions. Its lead candidate, HyBryteTM, a novel photodynamic therapy using synthetic hypericin for cutaneous T-cell lymphoma (CTCL), is in confirmatory Phase 3 trials with top-line results anticipated in the second half of 2026. The company is also developing synthetic hypericin for psoriasis (SGX302) and its Innate Defense Regulator (IDR) technology, dusquetide, for inflammatory diseases like oral mucositis and Behçet's Disease. The Public Health Solutions segment focuses on vaccine candidates for biodefense and emerging infectious diseases, utilizing its proprietary ThermoVax heat stabilization platform. Soligenix has historically relied on government grants and contract funding for its public health initiatives.

The company has no current revenues from product sales, as its product candidates are in development. Historically, revenue has been generated from government grants and contracts, primarily for the Public Health Solutions segment.